Publications
212 results found
Szydlo RM, Gabriel I, Olavarria E, et al., 2010, Sign of the Zodiac as a Predictor of Survival for Recipients of an Allogeneic Stem Cell Transplant for Chronic Myeloid Leukaemia (CML): An Artificial Association, TRANSPLANTATION PROCEEDINGS, Vol: 42, Pages: 3312-3315, ISSN: 0041-1345
- Author Web Link
- Cite
- Citations: 6
Gabriel IH, Sergeant R, Szydlo R, et al., 2010, Interaction between <i>KIR3DS1</i> and <i>HLA</i>-<i>Bw4</i> predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma, BLOOD, Vol: 116, Pages: 2033-2039, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 36
Jiao LR, Szydlo R, Habib NA, et al., 2010, Circulating Tumor Cells and Sample Size: The More, the Better Reply, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, Pages: E290-E290, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Dickinson AM, Pearce KF, Norden J, et al., 2010, Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol: 95, Pages: 922-927, ISSN: 0390-6078
- Author Web Link
- Cite
- Citations: 21
Pavlu J, Kew AK, Taylor-Roberts B, et al., 2010, Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase, BLOOD, Vol: 115, Pages: 4018-4020, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 46
Wong CL, Szydlo R, Gibbs S, et al., 2010, Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension, BLOOD COAGULATION & FIBRINOLYSIS, Vol: 21, Pages: 201-206, ISSN: 0957-5235
- Author Web Link
- Cite
- Citations: 42
Chilvers G, Szydlo R, Regan F, 2010, Feto-maternal haemorrhage does not account for the differences in cord blood volume obtained from Black and Asian <i>versus</i> Caucasoid donors, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 148, Pages: 951-953, ISSN: 0007-1048
Auner H, Mazzarella L, Cook L, et al., 2010, High rate of stem cell mobilization failure after thalidomide and cyclophosphamide induction therapy for myeloma, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: S21-S21, ISSN: 0268-3369
Pavlu J, Auner H, Ellis S, et al., 2010, LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: S255-S255, ISSN: 0268-3369
Malard F, Szydlo RM, Brissot E, et al., 2010, Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol: 16, Pages: 28-34, ISSN: 1083-8791
- Author Web Link
- Cite
- Citations: 62
Milojkovic D, Nicholson E, Apperley JF, et al., 2010, Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia, Haematologica, Vol: 95, Pages: 224-231-224-231
Background Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximately 50% of patients with chronic myeloid leukemia in chronic phase in whom imatinib treatment has failed. However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors.Design and Methods We analyzed a cohort of 80 patients with chronic myeloid leukemia who were resistant to imatinib and who were treated with dasatinib or nilotinib while still in first chronic phase. We devised a scoring system to predict the probability of these patients achieving complete cytogenetic response when treated with second-generation tyrosine kinase inhibitors.Results The system was based on three factors: cytogenetic response to imatinib, Sokal score and recurrent neutropenia during imatinib treatment. We validated the score in an independent group of 28 Scottish patients. We also studied the relationship between cytogenetic responses at 3, 6 and 12 months and subsequent outcome. We classified the 80 patients into three categories, those with good risk (n=24), intermediate risk (n=27) and poor risk (n=29) with 2.5-year cumulative incidences of complete cytogenetic response of 100%, 52.2% and 13.8%, respectively (P<0.0001). Moreover, patients who had less than 95% Philadelphia chromosome-positive metaphases at 3 months, those with 35% or less Philadelphia chromosome-positive metaphases at 6 months and patients in complete cytogenetic response at 12 months all had significantly better outcomes than patients with lesser degrees of cytogenetic response.Conclusions Factors measurable before starting treatment can accurately predict response to second-generation tyrosine kinase inhibitors. Cytogenetic responses at 3, 6 and 12 months may influence the decision to continue treatment with second-generation tyrosine kinase inhibitors.
Ibrahim AR, Paliompeis C, Bua M, et al., 2010, Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy, Blood, Vol: 116, Pages: 5497-5500-5497-5500
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second line were the only independent predictors for overall survival (OS). At 3 months, the 9 patients who had achieved a cytogenetic response had better 30-month probabilities of complete cytogenetic responses and OS than the patients who had failed to do so. Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions.
Marin D, Bazeos A, Mahon F-X, et al., 2010, Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib, Journal of Clinical Oncology, Vol: 28, Pages: 2381-2388-2381-2388
Purpose There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.Methods Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.Results Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence ≤ 90%; in 12 of these patients (14%), adherence was ≤ 80%. There was a strong correlation between adherence rate (≤ 90% or > 90%) and the 6-year probability of a 3-log reduction (also known as major molecular response [MMR]) in BCR-ABL1 transcripts (28.4% v 94.5%; P < .001) and also complete molecular response (CMR; 0% v 43.8%; P = .002). Multivariate analysis identified adherence (relative risk [RR], 11.7; P = .001) and expression of the molecular human organic cation transporter-1 (RR, 1.79; P = .038) as the only independent predictors for MMR. Adherence was the only independent predictor for CMR. No molecular responses were observed when adherence was ≤ 80% (P < .001). Patients whose imatinib doses were increased had poor adherence (86.4%). In this latter population, adherence was the only independent predictor for inability to achieve an MMR (RR, 17.66; P = .006).Conclusion In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.
Jiao LR, Apostolopoulos C, Jacob J, et al., 2009, Unique Localization of Circulating Tumor Cells in Patients With Hepatic Metastases, Journal of Clinical Oncology, Vol: 27, Pages: 6160-6165, ISSN: 0732-183X
PurposeThere are few data on the impact of immediate and differing surgical interventions on circulating tumorcells (CTCs), nor their compartmentalization or localization in different anatomic vascular sites.Patients and MethodsCTCs from consecutive patients with colorectal liver metastases were quantified before andimmediately after open surgery, laparoscopic resection, open radiofrequency ablation (RFA), orpercutaneous RFA. For individuals undergoing open surgery, either hepatic resections or openRFA, CTCs were examined in both systemic and portal circulation by measuring CTCs in samplesderived from the peripheral vein, an artery, the hepatic portal vein, and the hepatic vein.ResultsA total of 29 consecutive patients with colorectal liver metastases with a median age of 55 years(range, 30 to 88 years) were included. CTCs were localized to the hepatic portosystemicmacrocirculation with significantly greater numbers than in the systemic vasculature. Surgicalprocedures led to a statistically significant fall in CTCs at multiple sites measured. Conversely,RFA, either open or percutaneous, was associated with a significant increase in CTCs.ConclusionSurgical resection of metastases, but not RFA, immediately decreases CTC levels. In patients withcolorectal liver metastases, CTCs appear localized to the hepatic (and pulmonary) macrocirculations.This may explain why metastases in sites other than the liver and lungs are infrequentlyobserved in cancer.
Sheth A, de Melo VAS, Szydlo R, et al., 2009, Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma, CANCER GENETICS AND CYTOGENETICS, Vol: 194, Pages: 48-52, ISSN: 0165-4608
- Author Web Link
- Cite
- Citations: 1
Patel B, Kirkland KE, Szydlo R, et al., 2009, Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol: 94, Pages: 1399-1406, ISSN: 0390-6078
- Author Web Link
- Cite
- Citations: 26
Bower M, Veraitch O, Szydlo R, et al., 2009, Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease, BLOOD, Vol: 113, Pages: 4521-4524, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 40
Marin D, Khorashad JS, Foroni L, et al., 2009, Does a rise in the <i>BCR-ABL1</i> transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 145, Pages: 373-375, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 21
Khorashad JS, de Lavallade H, Apperley JF, et al., 2008, Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression, JOURNAL OF CLINICAL ONCOLOGY, Vol: 26, Pages: 4806-4813, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 139
Mohty M, Szydlo RM, Yong ASM, et al., 2008, Association between <i>BMI-1</i> expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia, BLOOD, Vol: 112, Pages: 2163-2166, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 18
de Lavallade H, Apperley JF, Khorashad JS, et al., 2008, Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis, JOURNAL OF CLINICAL ONCOLOGY, Vol: 26, Pages: 3358-3363, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 439
Nasilowska-Adamska B, Rzepecki P, Manko J, et al., 2007, The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant, BONE MARROW TRANSPLANTATION, Vol: 40, Pages: 983-988, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 49
Perz JB, Szydo R, Sergeant R, et al., 2007, Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab, TRANSPLANT IMMUNOLOGY, Vol: 18, Pages: 179-185, ISSN: 0966-3274
- Author Web Link
- Cite
- Citations: 6
Perz JB, Marin D, Szydlo RM, et al., 2007, Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation, LEUKEMIA RESEARCH, Vol: 31, Pages: 1433-1436, ISSN: 0145-2126
- Author Web Link
- Cite
- Citations: 6
Mohty M, Yong ASM, Szydlo RM, et al., 2007, The polycomb group <i>BMI1</i> gene is a molecular marker for predicting prognosis of chronic myeloid leukemia, BLOOD, Vol: 110, Pages: 380-383, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 114
Simula MP, Marktel S, Fozza C, et al., 2007, Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy, LEUKEMIA, Vol: 21, Pages: 943-948, ISSN: 0887-6924
- Author Web Link
- Cite
- Citations: 40
Fozza C, Szydlo RM, Abdel-Rehim MM, et al., 2007, Factors for graft-<i>versus</i>-host disease after donor lymphocyte infusions with an escalating dose regimen:: lack of association with cell dose, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 136, Pages: 833-836, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 24
Perz JB, Giles C, Szydlo R, et al., 2007, LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre, BONE MARROW TRANSPLANTATION, Vol: 39, Pages: 41-47, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 22
Hows JM, Passweg JR, Tichelli A, et al., 2006, Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors, BONE MARROW TRANSPLANTATION, Vol: 38, Pages: 799-805, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 45
Politou MC, Heath DJ, Rahemtulla A, et al., 2006, Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation, INTERNATIONAL JOURNAL OF CANCER, Vol: 119, Pages: 1728-1731, ISSN: 0020-7136
- Author Web Link
- Cite
- Citations: 129
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.